Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Melinta Therapeutics, LLC

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Joins NHIA Future of Infusion Advisory Council
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta’s Portfolio of Commercial and Investigational Stage Products
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics Announces the Appointment of Sunitha Lakshminarayanan, as Chief Technology Officer
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics Announces the Appointment of Fabrizio Tondolo, MD, as Vice President of Medical Affairs
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial of REZZAYO® (rezafungin for injection) for the Treatment of Candidemia & Invasive Candidiasis in The Lancet ID
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics Announces Commercial Availability of REZZAYO™ (rezafungin for injection)
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada
From Melinta Therapeutics, LLC
Via Business Wire
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
From Melinta Therapeutics, LLC
Via Business Wire
Tickers CDTX
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
From Melinta Therapeutics, LLC
Via Business Wire
Tickers CDTX
Melinta Therapeutics & OptimizeRx Announce 2022 Innovate4Outcomes Event
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics Announces Appointment of Peter Piliero as Vice President of Medical Affairs
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics President and CEO Christine Ann Miller Elected to Board of Directors of Iveric Bio
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy
From Melinta Therapeutics, LLC
Via Business Wire
Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer
From Melinta Therapeutics, LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.